Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

385
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
385
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

511
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
511
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

320
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
320
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

371
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
371
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

188
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
188
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

286
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
286

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-inflammatory potential of the CISACN adduct in LPS-induced murine models.

Inflammopharmacology·2026
Same author

Ribifolones A-H, New Macrocyclic Diterpenes from <i>Jatropha ribifolia</i>, Their Cytotoxic Activity and Insights Supported by Network Pharmacology and Molecular Modeling.

Molecules (Basel, Switzerland)·2026
Same author

Redox Disruption Induced by Saquayamycin B1 Promotes Cytotoxicity in Resistant Melanoma Cells.

ChemMedChem·2026
Same author

A Review of Pathophysiology and Computational Studies of Isoeugenol Derived Acetamides against Alzheimer's Disease.

Current topics in medicinal chemistry·2026
Same author

Tiliroside From Pavonia malacophylla (Link & Otto) Garcke as an Anti-SARS-CoV-2 Cell Entry Agent.

Chemistry & biodiversity·2026
Same author

Antinociceptive Effect of Cinnamaldehyde in Male Mice: Investigation of the Mechanisms of Action Through In Silico and In Vivo Approaches.

Chemistry & biodiversity·2026

Related Experiment Video

Updated: Jun 24, 2025

Electrophoretic Delivery of &#947;-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K

Multi-target Phenylpropanoids Against Epilepsy.

Teresa Carolliny Moreira Lustoza Rodrigues1, Arthur Lins Dias2, Aline Matilde Ferreira Dos Santos2

  • 1Cheminformatics Laboratory, Institute of Drugs and Medicines Research, Federal University of Paraíba, 58051-900, João Pessoa, Paraíba, Brazil.

Current Neuropharmacology
|June 7, 2024
PubMed
Summary
This summary is machine-generated.

Researchers explored natural compounds for epilepsy treatment. A phenylpropanoid derivative, TR430, showed promising multi-target activity by interacting with GABAA and AMPA receptors, suggesting a new avenue for epilepsy drug discovery.

Keywords:
AMPA.EpilepsyGABAAmolecular dockingmulti-targetphenylpropanoids

More Related Videos

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

33.0K
Planarian as an Animal Model for Experimental Acute Seizure
08:29

Planarian as an Animal Model for Experimental Acute Seizure

Published on: February 14, 2025

801

Related Experiment Videos

Last Updated: Jun 24, 2025

Electrophoretic Delivery of &#947;-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K
Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

33.0K
Planarian as an Animal Model for Experimental Acute Seizure
08:29

Planarian as an Animal Model for Experimental Acute Seizure

Published on: February 14, 2025

801

Area of Science:

  • Pharmacology
  • Neuroscience
  • Natural Products Chemistry

Background:

  • Epilepsy is a neurological disorder characterized by recurrent seizures due to neurotransmitter imbalance in the central nervous system (CNS).
  • Current antiepileptic drugs often have side effects and may require combination therapy, highlighting the need for novel therapeutic agents.
  • Natural products offer a rich source for discovering new drug candidates with potentially improved efficacy and safety profiles.

Purpose of the Study:

  • To investigate the potential antiepileptic and multi-target activities of phenylpropanoid derivatives using in silico methods.
  • To identify novel natural compounds that can modulate key targets involved in epilepsy pathogenesis.
  • To evaluate the pharmacokinetic and toxicological properties of promising candidate molecules.

Main Methods:

  • Ligand-based virtual screening (LBVS) of 468 phenylpropanoid compounds against epilepsy-related targets: AMPA, CaV, GABAA, GAT-1, KCNQ, NaV, and NMDA.
  • Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiling of compounds with favorable LBVS results.
  • Molecular docking consensus analysis to assess binding affinity and interactions with validated targets.

Main Results:

  • The phenylpropanoid derivative TR430 exhibited excellent pharmacokinetic properties, including 99.03% oral absorption and adherence to Lipinski's rule, with no observed cytotoxicity.
  • TR430 demonstrated significant binding affinity and interactions with both gamma-aminobutyric acid A (GABAA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.
  • TR430 showed potential for multi-target activity, acting as a GABAA activator and an AMPA inhibitor, key mechanisms in epilepsy treatment.

Conclusions:

  • TR430 is a promising natural compound with potential multi-target antiepileptic activity.
  • The identified compound warrants further investigation for its therapeutic potential in managing epilepsy.
  • In silico approaches are effective in discovering novel drug candidates from natural product libraries for neurological disorders.